Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 28;9(6):950-958.
doi: 10.7150/jca.21202. eCollection 2018.

Tumor location is an independent predictive factor for distant metastasis and metastatic sites of rectal adenocarcinoma in patients receiving total mesorectal excision

Affiliations

Tumor location is an independent predictive factor for distant metastasis and metastatic sites of rectal adenocarcinoma in patients receiving total mesorectal excision

Chien-Hsin Chen et al. J Cancer. .

Abstract

Background and Objectives: To evaluate the predictive factor for and patterns of distant metastasis in patients with rectal adenocarcinoma receiving total mesorectal excision (TME). Methods: We enrolled 217 consecutive patients who had histologically confirmed rectal adenocarcinoma and underwent surgery at Taipei Medical University- Wanfang Hospital between January 2000 and December 2014. TME was performed in all patients undergoing a sphincter-sparing procedure or abdominal perineal resection of rectal cancer. We performed univariate and multivariate Cox regression analyses of the distant metastasis rate in all patients to evaluate predictive factors. Overall survival (OS) rates were calculated using the Kaplan-Meier method, and Kaplan-Meier survival curves were compared using the log-rank test. Results: A multivariate Cox regression analysis of the distant metastasis rate in patients with rectal adenocarcinoma identified tumor locations and American Joint Committee on Cancer (AJCC) stages as prognostic risk factors. The adjusted hazard ratios (aHRs) of distant metastasis for the upper-third, middle-third, and AJCC stage I-II cancers were 0.08 (95% CI, 0.01-0.69; p = 0.021), 0.41 (95% CI, 0.15-0.99; p = 0.047), and 0.20 (95% CI, 0.10-0.66; p = 0.008), respectively. The 5-year lung metastasis rates among patients with upper-, middle-, and lower-third rectal cancers were 0%, 3.37%, and 13.33%, respectively (log-rank, p = 0.001), and the 5-year liver metastasis rates among patients with upper-, middle-, and lower-third rectal cancers were 2.12%, 9.10%, and 11.76%, respectively (log-rank, p = 0.096). The 5-year OS rates also differed with different rectal adenocarcinoma locations. The 5-year OS rates for upper, middle, and lower rectal cancers were 96%, 86%, and 64%, respectively (log-rank, p < 0.001). Conclusion: A poor OS rate and high lung or liver metastasis rate were observed in distal rectal adenocarcinoma. Longer intensive surveillance of the chest, abdomen, and pelvis after TME in distal rectal adenocarcinoma could be necessary.

Keywords: Rectal adenocarcinoma; distant metastasis; total mesorectal excision.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Five-year overall distant metastasis rates by different locations of rectal adenocarcinoma
Figure 2
Figure 2
Five-year lung metastasis rates by different locations of rectal adenocarcinoma
Figure 3
Figure 3
Five-year liver metastasis rates by different locations of rectal adenocarcinoma
Figure 4
Figure 4
Five-year overall survival rates by different locations of rectal adenocarcinoma

References

    1. National Health Insurance Administration, Ministry of Health, Welfare, Taiwan, R.O.CNational Health Insurance Annual Report 2014-2015. 2016.
    1. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S. et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I) British journal of cancer. 2010;102:1123–8. - PMC - PubMed
    1. Chen CH, Wei PL, Hsieh MC, Lin EK, Chiou JF, Lu YJ. et al. The outcomes of therapeutic decision in lower 3rd rectal cancer patients. Medicine (Baltimore) 2016;95:e4638. - PMC - PubMed
    1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479–82. - PubMed
    1. Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. The British journal of surgery. 1995;82:1297–9. - PubMed

LinkOut - more resources